Cargando…
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
It is well known that chemotherapy can cure only some cancers in advanced stage, mostly those with an intact p53 pathway. Hematological cancers such as lymphoma and certain forms of leukemia are paradigmatic examples of such scenario. Recent evidence indicates that the efficacy of many of the alkyla...
Autores principales: | Derenzini, Enrico, Rossi, Alessandra, Treré, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984324/ https://www.ncbi.nlm.nih.gov/pubmed/29855342 http://dx.doi.org/10.1186/s13045-018-0609-1 |
Ejemplares similares
-
The Ribosome Biogenesis—Cancer Connection
por: Penzo, Marianna, et al.
Publicado: (2019) -
Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?
por: Brighenti, Elisa, et al.
Publicado: (2015) -
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate
por: Brighenti, Elisa, et al.
Publicado: (2016) -
Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer
por: Brighenti, E, et al.
Publicado: (2014) -
The emerging role of RNA polymerase I transcription machinery in human malignancy: a clinical perspective
por: Montanaro, Lorenzo, et al.
Publicado: (2013)